Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.

Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, Golden L, Zhang W, Pitou C, Bell R, Campbell R, Farrington DL, Bell-McGuinn K, Wenham RM.

Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627-0. doi: 10.1016/j.ygyno.2019.11.006. [Epub ahead of print]


A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.

Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, Hynes S, Pitou C, Campbell R, Iversen P, Farrington DL, Bell-McGuinn K, Thomas M.

Invest New Drugs. 2019 Nov 9. doi: 10.1007/s10637-019-00873-6. [Epub ahead of print]


Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.

Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF.

AAPS J. 2019 Jan 31;21(2):23. doi: 10.1208/s12248-018-0291-9.


Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C, Li PL, Gerds AT.

Leuk Res. 2018 Aug;71:82-88. doi: 10.1016/j.leukres.2018.06.014. Epub 2018 Jun 30.


Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.

Parra-Guillen ZP, Mangas-Sanjuan V, Garcia-Cremades M, Troconiz IF, Mo G, Pitou C, Iversen PW, Wallin JE.

J Pharmacol Exp Ther. 2018 Jul;366(1):96-104. doi: 10.1124/jpet.118.248286. Epub 2018 Apr 24.


Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.

Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu RV, Pitou C, Tucker T, Brail L, Von Hoff D.

Clin Cancer Res. 2018 May 1;24(9):2082-2091. doi: 10.1158/1078-0432.CCR-17-0723. Epub 2018 Feb 26.


Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.

Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF.

Eur J Pharm Sci. 2018 Mar 30;115:296-303. doi: 10.1016/j.ejps.2018.01.033. Epub 2018 Jan 31.


Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.

Invest New Drugs. 2018 Aug;36(4):629-637. doi: 10.1007/s10637-017-0532-2. Epub 2017 Dec 1.


A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT.

Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.


Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.

Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF.

J Pharmacol Exp Ther. 2017 Mar;360(3):445-456. doi: 10.1124/jpet.116.237610. Epub 2016 Dec 27.


A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.


Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD.

Clin Pharmacol Ther. 2015 Jul;98(1):76-86. doi: 10.1002/cpt.128. Epub 2015 May 19. Review.


A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.

Cohn A, Lahn MM, Williams KE, Cleverly AL, Pitou C, Kadam SK, Farmen MW, Desaiah D, Raju R, Conkling P, Richards D.

Int J Oncol. 2014 Dec;45(6):2221-31. doi: 10.3892/ijo.2014.2679. Epub 2014 Sep 26.


Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.

Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP.

Blood Cancer J. 2013 Apr 12;3:e109. doi: 10.1038/bcj.2013.6.


Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.

Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF.

Eur J Cancer. 2008 Jan;44(1):142-50. Epub 2007 Nov 26.


Supplemental Content

Support Center